{"product_id":"a-new-approach-to-breast-cancer-surgery-what-patients-should-know-about-treatment-after-neoadjuvant-therapy","title":"A New Approach to Breast Cancer Surgery: What Patients Should Know About Treatment After Neoadjuvant Therapy","description":"\u003cp\u003eResearchers in this comprehensive review examined how surgical treatment for locally advanced breast cancer (LABC) is evolving after patients receive neoadjuvant systemic therapy (NST) — chemotherapy or targeted treatment given before surgery. The review found that while mastectomy with full lymph node removal has been the traditional standard, newer evidence suggests that breast-conserving surgery and immediate reconstruction can be safe for carefully selected patients who respond well to NST, and that less invasive lymph node procedures may effectively replace more extensive surgery in certain cases. With pathological complete response rates now exceeding 30% in HER2-positive and triple-negative breast cancer subtypes, the authors emphasize that personalized surgical decisions based on tumor response, molecular subtype, and careful imaging assessment are becoming increasingly important. The article also highlights ongoing clinical trials that may further refine which patients can safely avoid surgery altogether, while cautioning that more high-quality evidence is still needed.\u003c\/p\u003e\n\n\u003ch1\u003eA New Approach to Breast Cancer Surgery: What Patients Should Know About Treatment After Neoadjuvant Therapy\u003c\/h1\u003e\n\n\u003ch2\u003eTable of Contents\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca href=\"#ddn-key-points\"\u003eKey Points\u003c\/a\u003e\u003c\/li\u003e\n\n  \u003cli\u003e\u003ca href=\"#background\"\u003eUnderstanding Locally Advanced Breast Cancer\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#evaluating-response\"\u003eHow Doctors Evaluate Treatment Response\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#omitting-surgery\"\u003eCan Surgery Be Omitted Entirely?\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#breast-conserving\"\u003eBreast-Conserving Surgery: A Safe Option?\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#reconstruction\"\u003eImmediate Breast Reconstruction After NST\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#lymph-node-management\"\u003eAxillary Lymph Node Management After NST\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#skipping-alnd\"\u003eWhen Can Full Lymph Node Removal Be Avoided?\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#clinical-implications\"\u003eClinical Implications: What This Means for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#limitations\"\u003eLimitations of the Research\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#recommendations\"\u003eRecommendations for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#source-information\"\u003eSource Information\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#ddn-faq\"\u003eFrequently Asked Questions\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- ddn:keypoints:start --\u003e\n\u003ch2 id=\"ddn-key-points\"\u003eKey Points\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003ePathological complete response occurs in over 30% of HER2-positive and triple-negative breast cancer patients after neoadjuvant therapy.\u003c\/li\u003e\n\u003cli\u003eBreast-conserving surgery appears safe for selected locally advanced breast cancer patients who respond well to neoadjuvant therapy.\u003c\/li\u003e\n\u003cli\u003eImmediate reconstruction is generally safe, but caution is advised for tumors larger than 3 cm or inflammatory breast cancer.\u003c\/li\u003e\n\u003cli\u003eSentinel lymph node biopsy may replace full lymph node removal in patients whose positive nodes become negative after treatment.\u003c\/li\u003e\n\u003cli\u003eReceiving radiation before surgery can shorten overall treatment time for patients needing both reconstruction and radiation.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- ddn:keypoints:end --\u003e\n\n\n\u003ch2 id=\"background\"\u003eUnderstanding Locally Advanced Breast Cancer\u003c\/h2\u003e\n\n\u003cp\u003eLocally advanced breast cancer (LABC) refers to cancers that have grown significantly within the breast or spread to nearby tissues and lymph nodes, but have not yet spread to distant organs. Traditionally, these are stage III cancers where surgery alone is not possible without first shrinking the tumor with systemic (whole-body) treatment. These cancers carry an elevated risk of recurrence and metastasis, yet they \u003cem\u003ecan\u003c\/em\u003e still be cured if doctors achieve good local control of the disease.\u003c\/p\u003e\n\n\u003cp\u003eWhile routine screening programs have made LABC relatively uncommon in developed countries, it remains a major challenge in developing nations. For example, in India, 47% of breast cancer cases are already at stage III when first diagnosed — a striking statistic that highlights the global burden of this disease.\u003c\/p\u003e\n\n\u003cp\u003eThe treatment landscape has shifted dramatically in recent years. Thanks to dual HER2 blockade (targeting the human epidermal growth factor receptor 2 protein) and platinum-based neoadjuvant chemotherapy, the rate of pathological complete response (pCR) — meaning no cancer cells remain in the removed tissue — has increased to more than 30% in HER2-positive and triple-negative breast cancer (TNBC) patients. As the overall philosophy of breast cancer treatment moves from \"maximum tolerable treatment\" to \"minimum effective treatment,\" doctors are increasingly asking whether patients with LABC have safer, less extensive surgical options available to them.\u003c\/p\u003e\n\n\u003ch2 id=\"evaluating-response\"\u003eHow Doctors Evaluate Treatment Response\u003c\/h2\u003e\n\n\u003cp\u003eAssessing how well a tumor responds to NST before surgery is essential for tailoring personalized surgical plans. When patients achieve a clinical complete response (cCR) — meaning no cancer can be detected by physical examination or imaging — doctors may even consider skipping surgery altogether, although this remains highly controversial.\u003c\/p\u003e\n\n\u003cp\u003eMagnetic resonance imaging (MRI) is currently the most accurate imaging method for predicting pCR and identifying residual disease, outperforming clinical examination, ultrasound, and mammography. However, MRI is far from perfect. It can overestimate residual disease due to fibrosis (scar-like tissue), necrotic (dead) tumors, or benign masses. Conversely, it can underestimate disease in cases involving no clear mass lesions, invasive lobular carcinoma, hormone receptor-positive (HR+) tumors, non-concentric shrinkage patterns (where the tumor shrinks unevenly), antiangiogenic therapy effects, or late-enhancing foci on imaging.\u003c\/p\u003e\n\n\u003cp\u003eCritically, MRI accuracy varies significantly by breast cancer subtype. Sensitivity is highest in triple-negative breast cancer and lowest in HR+\/HER2− subtypes. Because imaging alone is insufficient, researchers have explored image-guided minimally invasive biopsy (MIB) techniques — including core needle biopsy (CNB), vacuum-assisted biopsy (VAB), and fine-needle aspiration (FNA) — to determine whether the breast has achieved pCR after NST.\u003c\/p\u003e\n\n\u003cp\u003eOne study by Sutton and colleagues found that MRI-guided VAB could increase the accuracy of predicting pCR to 95%. However, another study by van Hemert and colleagues found that small residual lesions measuring just 4–7 mm are often missed during biopsy procedures. A meta-analysis of nine trials involving 1,030 breast cancer patients found that while MIB is highly specific, its sensitivity is limited. Specifically, the pooled sensitivity was 0.72 (95% confidence interval: 0.61–0.81), and the pooled specificity was 0.99 (95% CI: 0.89–1.00). In plain language: if MIB says cancer is present, it's almost certainly correct (99% specificity), but if MIB says no cancer is present, there's about a 28% chance that small residual cancer was actually missed.\u003c\/p\u003e\n\n\u003ch2 id=\"omitting-surgery\"\u003eCan Surgery Be Omitted Entirely?\u003c\/h2\u003e\n\n\u003cp\u003eWhether patients who achieve cCR or pCR can be exempted from breast surgery has been explored in prior retrospective studies. Research by Ring and Clouth, which included patients with stage III breast cancer, found that omitting breast surgery does not appear to affect long-term survival outcomes. However, the authors note that no studies have specifically examined surgery exemption in LABC patients.\u003c\/p\u003e\n\n\u003cp\u003eA multicenter phase II clinical trial (NCT02945579) led by MD Anderson Cancer Center is currently exploring the possibility of omitting surgery after NST — but notably, it has excluded LABC patients, reflecting ongoing uncertainty about this approach in more advanced disease.\u003c\/p\u003e\n\n\u003cp\u003eThere is important debate about what pCR actually means for patients. A pooled analysis published in \u003cem\u003eThe Lancet\u003c\/em\u003e showed that patients who achieve pCR enjoy improved long-term survival rates. However, a more recent meta-analysis of 54 clinical studies found only a \u003cem\u003eweak\u003c\/em\u003e association between pCR and both disease-free survival (DFS) — time without cancer recurrence — and overall survival (OS). This meta-analysis concluded that pCR should not be the primary endpoint in trials of NST for breast cancer. Currently, no method exists to accurately assess pCR in living patients without surgery, and even patients with LABC who achieve pCR are not yet exempt from surgery.\u003c\/p\u003e\n\n\u003ch2 id=\"breast-conserving\"\u003eBreast-Conserving Surgery: A Safe Option?\u003c\/h2\u003e\n\n\u003cp\u003eOne of the most pressing questions is whether breast-conserving surgery (BCS) — removing only the tumor and a margin of surrounding tissue rather than the entire breast — is safe for LABC patients who respond well to NST. The crucial element for BCS is achieving a negative pathological margin (no cancer cells at the edge of removed tissue). This depends heavily on understanding the tumor's shrinkage pattern.\u003c\/p\u003e\n\n\u003cp\u003eWang and colleagues classified residual tumor morphology after NST into three categories:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIsolated residual tumors\u003c\/strong\u003e — the most common pattern, seen in 61% of cases, where the tumor shrinks concentrically (evenly from the outside in)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMultifocal and patchlike patterns\u003c\/strong\u003e — seen in 33% of cases, where tumor cells remain in scattered patches\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMain residues with satellite lesions\u003c\/strong\u003e — seen in 6% of cases\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe size of the primary tumor directly influences its shrinkage pattern. Larger tumors more often show non-concentric shrinkage, which complicates the ability to achieve negative margins. BCS after NST is therefore theoretically limited mostly to tumors that shrink concentrically. For multiple lesions within the same quadrant of the breast, BCS can sometimes still be attempted.\u003c\/p\u003e\n\n\u003cp\u003eBi and colleagues conducted a study using 3D MRI reconstruction of residual tumors, suggesting that a 50% reduction in the longest tumor diameter plus a residual size of ≤2 cm after NST could qualify patients for BCS. After a median follow-up of 77 months, the rate of recurrence or metastasis in these patients was just 7.1% — suggesting this approach identifies a group where BCS is reasonably safe.\u003c\/p\u003e\n\n\u003cp\u003eRegarding surgical margins, the National Comprehensive Cancer Network (NCCN) and St. Gallen consensus define negative margins for BCS after NST as \"no ink on tumor\" — the same standard used for BCS without NST. However, a 2022 meta-analysis published in the \u003cem\u003eBritish Medical Journal\u003c\/em\u003e challenged this standard. The analysis found that close margins (defined as no tumor on ink but less than 2 mm of clear tissue) were linked to a higher risk of local recurrence and metastasis compared to negative margins (2 mm or more), even after accounting for adjuvant chemotherapy and radiotherapy (P \u0026lt; 0.001). This finding raises genuine concerns about whether the \"no tumor on ink\" standard is adequate for BCS after NST.\u003c\/p\u003e\n\n\u003cp\u003eIn several retrospective studies, the rate of BCS after NST in LABC patients ranged from \u003cstrong\u003e12.5% to 43.4%\u003c\/strong\u003e. BCS appears to be oncologically safe for LABC patients who respond well to NST. Patients more frequently selected for BCS included younger women, those with smaller tumors, and those achieving pCR. Additionally, patients in the NST-BCS group were more commonly found to have HER2+\/HR− or triple-negative breast cancer, as well as non-invasive lobular carcinoma, compared to patients who underwent mastectomy.\u003c\/p\u003e\n\n\u003cp\u003eA meta-analysis of 16 studies by Sun and colleagues found no significant difference in local recurrence-free survival (LRFS) between BCS and mastectomy groups (P = 0.26). However, disease-free survival and overall survival were actually \u003cem\u003ehigher\u003c\/em\u003e in the BCS group (P \u0026lt; 0.01). This may be explained by the higher pCR rates seen in BCS patients, since pCR is associated with improved outcomes. While these results suggest BCS is safe for LABC patients with a favorable NST response, all referenced studies are retrospective, meaning high-quality prospective evidence is still needed to firmly confirm these conclusions.\u003c\/p\u003e\n\n\u003ch2 id=\"reconstruction\"\u003eImmediate Breast Reconstruction After NST\u003c\/h2\u003e\n\n\u003cp\u003eBreast reconstruction offers patients who cannot undergo BCS an opportunity for a more aesthetically pleasing breast shape and helps mitigate some of the negative psychological effects of total mastectomy. Immediate reconstruction (IR) is associated with higher physical and psychological satisfaction compared to delayed reconstruction, and patients desiring reconstruction may opt for IR without compromising safety.\u003c\/p\u003e\n\n\u003cp\u003eSeveral surgical techniques allow for IR, including nipple-sparing, skin-sparing, and skin-reducing mastectomies. Nipple-sparing mastectomies require a negative margin at the back of the nipple-areola complex. While high-quality evidence confirming the oncological safety of nipple-sparing mastectomy with reconstruction is lacking, multiple retrospective studies suggest that IR after NST does not increase the risk of local recurrence or harm long-term survival.\u003c\/p\u003e\n\n\u003cp\u003eMeli and colleagues found no significant difference in local recurrence or survival between patients who underwent nipple-sparing mastectomy with or without NST, suggesting IR is a viable and safe option. Similarly, Wu and colleagues found no significant differences in long-term outcomes — including 5-year LRFS, DFS, or OS — between patients who had IR after NST and those who had no reconstruction. This reinforces the safety and desirability of IR.\u003c\/p\u003e\n\n\u003cp\u003eHowever, some caution is advised. Song and colleagues found that patients with tumors exceeding 3 cm who received IR had a lower 5-year DFS compared to those who had no reconstruction, suggesting that IR may be more appropriate for smaller tumors (≤3 cm). For stage T4 breast cancer — particularly inflammatory breast cancer — Pawloski and colleagues found that IR significantly increased the likelihood of postoperative complications and delayed the start of radiotherapy, often by more than 8 weeks. Due to these complications and the observation that the average time to first recurrence was 18 months within a median follow-up of 4.2 years, the study recommended postponing reconstruction for at least 18 months after surgery in these high-risk cases.\u003c\/p\u003e\n\n\u003cp\u003eWu and colleagues reported no significant differences in LRFS, DFS, or OS between patients with poor responses to NST who underwent nipple-sparing or skin-sparing IR and those who had mastectomy alone. This suggests that the response to NST should not be the sole determining factor when choosing IR. A meta-analysis of 17 studies involving 3,249 patients examined the effect of NST on postoperative complications associated with IR. The analysis found that NST did not significantly raise the overall risk of postoperative complications (P = 0.34). However, it did show a statistically significant increase in the rate of implant or expander loss (P = 0.03). This means that while NST does not broadly elevate complication risk, it may specifically heighten the risk of implant-related problems.\u003c\/p\u003e\n\n\u003cp\u003eThere is widespread agreement that postmastectomy radiation therapy (PMRT) can lead to skin discoloration and shrinking of the nipple-areola complex. The 2022 recommendations from the Oncoplastic Breast Consortium generally agree that PMRT raises the risk of complications in all forms of implant-based breast reconstruction. Most experts concur that PMRT carries a lower overall long-term risk of complications after immediate autologous (using the patient's own tissue) reconstruction compared to implant-based reconstruction.\u003c\/p\u003e\n\n\u003cp\u003eTo avoid delaying PMRT after IR, a \"reverse sequence\" (RS) approach has been proposed: NST, followed by \u003cem\u003epreoperative\u003c\/em\u003e radiotherapy, then mastectomy and IR. Paillocher and colleagues studied 111 patients who underwent this RS approach, with a median follow-up of 31.6 months. The 5-year DFS was 93.2% and OS was 98.3%, with high patient satisfaction (scored 17 out of 20). In the RS group, radiotherapy was feasible just 4 weeks after the end of NST, while immediate autologous latissimus dorsi breast reconstruction was feasible 6–8 weeks after radiotherapy concluded in the standard sequence (SS) group. The RS approach significantly shortened overall treatment time.\u003c\/p\u003e\n\n\u003cp\u003eMaire and colleagues compared RS and SS approaches using the autologous latissimus dorsi flap with or without an implant. With a median follow-up of 61.7 months, there was no significant difference between the groups in OS (P = 0.44) or recurrence-free survival (P = 0.30). Postoperative morbidity also did not differ significantly (P = 0.51). In the RS group, the average time from the end of radiotherapy to surgery was 5.9 weeks, compared to 8.4 weeks in the SS group from surgery to the start of radiotherapy — a highly significant reduction in treatment time (P \u0026lt; 0.001). An ongoing single-arm clinical trial (NCT05412225) is further investigating preoperative radiotherapy followed by total mastectomy and autologous IR in LABC patients, aiming to avoid delays in radiotherapy after reconstruction.\u003c\/p\u003e\n\n\u003cp\u003eFor LABC patients considering reconstruction, doctors should ensure they fully understand the process, risks, and benefits, and have clear expectations about surgical results. Patients with initially large tumors should approach IR with great caution. For T4 stage disease, especially inflammatory breast cancer, IR is not recommended. Patients who wish to reconstruct and need radiation therapy may benefit from receiving radiation before surgery after NST to shorten overall treatment time while preserving breast aesthetics after reconstruction.\u003c\/p\u003e\n\n\u003ch2 id=\"lymph-node-management\"\u003eAxillary Lymph Node Management After NST\u003c\/h2\u003e\n\n\u003cp\u003eThe use of NST has fundamentally changed how doctors manage the lymph nodes under the arm (axillary lymph nodes). Traditionally, axillary lymph node dissection (ALND) — surgical removal of most lymph nodes in the armpit — was performed for all patients with clinically positive nodes (cN+). Recent efforts have explored less invasive alternatives, aiming to reduce surgical morbidity (including lymphedema, or arm swelling) while maintaining oncological safety.\u003c\/p\u003e\n\n\u003cp\u003eA meta-analysis of 33 studies revealed that axillary lymph node pCR rates after NST vary substantially by breast cancer subtype in patients who initially had positive nodes (cN+):\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHR−\/HER2+\u003c\/strong\u003e (hormone receptor-negative, HER2-positive): 60% pCR rate\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHR+\/HER2+\u003c\/strong\u003e: 45% pCR rate\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHR−\/HER2−\u003c\/strong\u003e (triple-negative): 48% pCR rate\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHR+\/HER2−\u003c\/strong\u003e: 18% pCR rate (the lowest)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThis suggests that patients with HER2+ and triple-negative breast cancer — the subtypes most likely to achieve nodal clearance — may be the best candidates for less extensive axillary surgery.\u003c\/p\u003e\n\n\u003cp\u003eData from the Netherlands Cancer Registry revealed a notable shift in practice between 2006 and 2016. The rate of patients with initially negative axillary lymph nodes (cN0) who underwent sentinel lymph node biopsy (SLNB) — a procedure that removes only the first few \"sentinel\" nodes draining the breast — after NST rose from 33% to 62%. Simultaneously, the rate of patients with cN+ who underwent ALND decreased dramatically, from 99% to 63% (P \u0026lt; 0.01). This reflects a significant real-world movement toward less invasive approaches.\u003c\/p\u003e\n\n\u003cp\u003eHowever, the European Breast Cancer Research Association of Surgical Trialists (EUBREAST) conducted a global survey in 2020 that highlighted significant disagreement among experts about axillary management after NST. Key points of contention include whether ALND can be omitted for patients whose positive nodes become negative after treatment (cN+→ypN0) and how to manage patients whose sentinel lymph nodes (SLNs) show only isolated tumor cells (ypN0[i+]) or micrometastases (ypN1[mi]) — tiny clusters of cancer cells visible only under a microscope.\u003c\/p\u003e\n\n\u003cp\u003eData from large clinical trials have found that NST can potentially increase the \"false negative rate\" (FNR) of SLNB — meaning the SLNB misses cancer that is actually present in other lymph nodes. This occurs because NST can alter axillary lymphatic drainage patterns, disrupt lymphatic structures, and induce fibrosis (scarring). Several meta-analyses have confirmed that using dual-tracer sampling (two different dyes\/markers) and removing a minimum of three sentinel nodes effectively reduces the false negative rate. Additionally, a strategy called targeted axillary dissection (TAD) — which involves marking biopsied positive nodes before starting NST and then removing those specific marked nodes along with sentinel nodes during surgery — has been shown to effectively reduce FNR. Research from Anderson Cancer Center revealed false negative rates of 10.1% for SLNB alone versus just 1.4% for SLNB combined with TAD (P = 0.03) — a dramatic improvement in accuracy.\u003c\/p\u003e\n\n\u003ch2 id=\"skipping-alnd\"\u003eWhen Can Full Lymph Node Removal Be Avoided?\u003c\/h2\u003e\n\n\u003cp\u003eWhether patients whose positive lymph nodes convert to negative (cN+→ypN0) can safely skip ALND remains somewhat controversial in clinical guidelines. Several retrospective studies provide reassuring data:\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eBarrio and colleagues\u003c\/strong\u003e analyzed a cohort of 610 patients diagnosed with cN1 (cancer in one to three lymph nodes). Among those who achieved ypN0 (negative nodes after treatment), 91% underwent SLNB alone. Forty-two percent of these patients had three or more SLNs removed, and 70% received regional nodal irradiation (RNI) — radiation to the lymph node area. At a median follow-up of 40 months, axillary recurrence was seen in only \u003cem\u003eone\u003c\/em\u003e patient, who notably did not receive RNI. This study suggests that cN1→ypN0 patients with three or more negative SLNs may not require ALND.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eTinterri and colleagues\u003c\/strong\u003e studied 291 patients who were ypN0 after SLNB, including 131 who were originally cN0 and 160 who were cN+. After a median follow-up of 43 months, axillary lymph node recurrence rates were 2.3% for cN0 patients and 1.3% for cN+ patients — very low in both groups. There were no significant differences in DFS or OS between the cN0 and cN+ groups, nor between those who had SLNB versus those who had ALND.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eKahler and colleagues\u003c\/strong\u003e analyzed 688 ypN0 patients after SLNB with a median follow-up of 9.2 years — one of the longest follow-up periods in this area. They observed axillary recurrence rates of 1.8% for cN0 patients and 1.5% for cN1-2 patients, with no significant differences in DFS or OS between the groups.\u003c\/p\u003e\n\n\u003cp\u003eThese retrospective studies consistently show that cN+→ypN0 patients do not necessarily need ALND. However, limitations exist. Tinterri's study lacked detailed information about the cN+ patients, and Kahler's study included only 12 cases of cN2 (more extensive nodal disease).\u003c\/p\u003e\n\n\u003cp\u003eIn contrast, \u003cstrong\u003ePark and colleagues\u003c\/strong\u003e analyzed data from \u003cstrong\u003e22,156 cN2-3 patients\u003c\/strong\u003e in the National Cancer Database. Of these, 2,190 (9.9%) underwent SLNB while the majority (19,966) had ALND. After adjusting for relevant factors, the study found that ALND was actually linked to a \u003cem\u003ereduced\u003c\/em\u003e risk of mortality compared to SLNB — even in patients who achieved pCR. This finding serves as an important counterweight to the more optimistic studies above, suggesting that for patients with more advanced nodal disease (cN2-3), ALND may still offer a survival benefit.\u003c\/p\u003e\n\n\u003cp\u003eIn a study by \u003cstrong\u003eLim and colleagues\u003c\/strong\u003e, 477 patients with cN1→ypN0 were analyzed. At a median follow-up of 65 months, patients who underwent ALND had worse DFS (P = 0.011) and worse OS (P = 0.0476) compared to those who had only SLNB. However, the ALND group contained a higher number of patients with larger tumors (T3-4). When the researchers looked only at patients with smaller tumors (cT1-2), there was no significant difference in DFS or OS between the ALND and SLNB groups. This suggests that less invasive surgery may be appropriate specifically for patients with smaller primary tumors.\u003c\/p\u003e\n\n\u003cp\u003eThe AXSANA trial — a large, multi-center prospective study — aims to recruit a total of 3,000 patients by the year 2030. Its purpose is to evaluate the feasibility and safety of various surgical techniques including ALND, SLNB, and TAD in patients with positive lymph nodes. Results from this trial will be crucial in settling these questions with high-quality prospective data.\u003c\/p\u003e\n\n\u003cp\u003eConcerning patients with isolated tumor cells (ypN0[i+]) or micrometastases (ypN1[mi]) in their sentinel nodes, the international multicenter retrospective OPBC-05\/ICARO study examined 583 patients with ypN0(i+). Among them, 182 received ALND while 401 did not. Of those who underwent ALND, 30% were found to have additional positive nodes. Yet there was no significant difference in the 5-year rates of local recurrence-free survival, overall survival, or disease-free survival between those who had ALND and those who did not. This study concluded that routine ALND may not be necessary for this patient population. A separate study of ypN0(i+) and ypN1(mi) patients after neoadjuvant \u003cem\u003eendocrine\u003c\/em\u003e therapy similarly found no significant differences in outcomes between those who underwent ALND and those who did not.\u003c\/p\u003e\n\n\u003cp\u003eExisting studies present conflicting findings regarding whether ypN0(i+) and ypN1(mi) patients can be exempted from ALND. In the EUBREAST survey, expert opinion was notably divided: 32.3% of experts recommended no additional treatment for ypN0(i+) patients, while 33.1% suggested regional nodal irradiation. For ypN1(mi) patients, 34.8% of experts recommended ALND while 30.4% preferred RNI. The prevailing view at the 2021 St. Gallen Conference, however, leaned toward regional nodal irradiation for these patients.\u003c\/p\u003e\n\n\u003ch2 id=\"clinical-implications\"\u003eClinical Implications: What This Means for Patients\u003c\/h2\u003e\n\n\u003cp\u003eFor patients with locally advanced breast cancer, these findings point to an era of increasingly personalized surgical decision-making. The key takeaways are:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eResponse matters:\u003c\/strong\u003e Patients who achieve a strong response to NST — particularly those with HER2+ or triple-negative breast cancer — may have more surgical options available to them, including breast-conserving surgery and immediate reconstruction.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eLess may be more:\u003c\/strong\u003e For selected patients whose lymph nodes convert from positive to negative after NST, sentinel lymph node biopsy (especially with three or more nodes removed or targeted axillary dissection) may be a safe alternative to full axillary dissection, reducing the risk of lymphedema and other complications.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTiming innovation:\u003c\/strong\u003e The reverse sequence approach — delivering radiation before surgery — may help patients who need both reconstruction and radiation complete their treatment faster without compromising outcomes.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eNot for everyone:\u003c\/strong\u003e Patients with large tumors (over 3 cm), T4 disease, or inflammatory breast cancer should be cautious about immediate reconstruction, as risks of complications and treatment delays appear higher.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSurgical decisions affect survival:\u003c\/strong\u003e The choice between BCS and mastectomy, or between SLNB and ALND, appears to be associated with differences in long-term survival outcomes — though whether this reflects the surgery itself or the underlying biology of patients selected for each approach remains unclear.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2 id=\"limitations\"\u003eLimitations of the Research\u003c\/h2\u003e\n\n\u003cp\u003eThe authors of this review are transparent about the limitations of the evidence base. Most of the studies on BCS, immediate reconstruction, and axillary management in LABC patients after NST are \u003cstrong\u003eretrospective\u003c\/strong\u003e — they look back at patient records rather than randomly assigning patients to different treatments. Retrospective studies are subject to selection bias: patients who received BCS or SLNB may have had more favorable characteristics to begin with (younger age, smaller tumors, better responses to treatment), which could explain some of the better outcomes seen in these groups.\u003c\/p\u003e\n\n\u003cp\u003eOther limitations include:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eNo studies have specifically examined omitting surgery entirely in LABC patients — the existing trials on this question have excluded this population.\u003c\/li\u003e\n  \u003cli\u003eMRI and minimally invasive biopsy techniques cannot yet perfectly predict pCR, particularly missing small residual lesions of 4–7 mm.\u003c\/li\u003e\n  \u003cli\u003eThe \"no ink on tumor\" margin standard for BCS after NST has been challenged by a major 2022 meta-analysis, but high-level evidence to establish an alternative standard is lacking.\u003c\/li\u003e\n  \u003cli\u003eThe optimal margin width for BCS in the NST setting remains uncertain.\u003c\/li\u003e\n  \u003cli\u003eSome studies included very few patients with advanced nodal disease (e.g., only 12 cN2 cases in one study), limiting the ability to draw conclusions for this higher-risk group.\u003c\/li\u003e\n  \u003cli\u003eConflicting results — particularly regarding ALND's value in cN2-3 patients — highlight that \"one size fits all\" recommendations are not possible with current evidence.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2 id=\"recommendations\"\u003eRecommendations for Patients\u003c\/h2\u003e\n\n\u003cp\u003eBased on this review, here are practical considerations for patients facing surgical decisions after neoadjuvant therapy for locally advanced breast cancer:\u003c\/p\u003e\n\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDiscuss your individual response to NST with your surgical team.\u003c\/strong\u003e Your specific tumor response — including whether you achieved pCR, your molecular subtype (HER2+, triple-negative, or hormone receptor-positive), and imaging findings — should guide your surgical options. Ask your doctor what your imaging and biopsy results indicate about your response.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAsk about breast-conserving surgery if you've responded well.\u003c\/strong\u003e If your tumor has shrunk significantly (especially to 2 cm or less with a 50% reduction in diameter), BCS may be a safe option. Rates of BCS in LABC patients who respond well to NST range from 12.5% to 43.4% in published studies, and long-term outcomes appear comparable to mastectomy in carefully selected patients.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eUnderstand the margin question.\u003c\/strong\u003e Ask your surgeon what surgical margin they will aim for. Recent evidence suggests that margins of 2 mm or more may be safer than \"no ink on tumor\" alone in the post-NST setting, though this is still debated.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIf considering reconstruction, discuss timing and technique.\u003c\/strong\u003e Immediate reconstruction is generally safe after NST and offers better cosmetic and psychological outcomes. However, if your tumor was large (\u0026gt;3 cm) or you have inflammatory breast cancer, your surgical team may recommend postponing reconstruction or avoiding it until the risk of recurrence is better understood. Ask about the risk of implant-related complications (which is higher after NST).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAsk about the reverse sequence approach.\u003c\/strong\u003e If you need both reconstruction and radiation therapy, ask whether receiving radiation before surgery might be an option. Studies suggest this approach can shorten your overall treatment time by several weeks without compromising outcomes.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAsk about lymph node management.\u003c\/strong\u003e If your lymph nodes were positive before NST but appear to have cleared with treatment, ask whether you are a candidate for sentinel lymph node biopsy alone rather than full axillary dissection. Evidence suggests this is reasonable for patients with cN1 disease, at least three negative sentinel nodes examined, and plans for regional nodal irradiation. Ask specifically about whether targeted axillary dissection (removing previously marked positive nodes) is available at your center — this technique has a false negative rate of just 1.4% compared to 10.1% for standard SLNB.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eParticipate in clinical trials if eligible.\u003c\/strong\u003e The AXSANA trial (recruiting 3,000 patients by 2030) and NCT05412225 are actively investigating these questions. Ask your care team whether any open trials might be appropriate for your situation — the results will shape future surgical recommendations for LABC patients.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eRemember the whole picture.\u003c\/strong\u003e The goal of surgical management in LABC is not just removing cancer — it's maximizing long-term survival while preserving quality of life. These goals are complementary, not competing. An honest, thorough discussion with your multidisciplinary care team about your individual risk profile, treatment options, and personal priorities is essential.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003c!-- ddn:faq:start --\u003e\n\u003ch2 id=\"ddn-faq\"\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eWhat is locally advanced breast cancer?\u003c\/h3\u003e\n\u003cp\u003eLocally advanced breast cancer has grown significantly within the breast or spread to nearby tissues and lymph nodes, but not to distant organs. It is often stage III. Surgery alone is not possible at first; systemic treatment is given before surgery to shrink the tumor.\u003c\/p\u003e\n\u003ch3\u003eHow do doctors check whether chemotherapy worked before surgery?\u003c\/h3\u003e\n\u003cp\u003eDoctors use breast MRI plus physical exam and sometimes image-guided biopsy. MRI is the most accurate imaging test, but it can miss small residual tumors (4–7 mm) or overestimate disease due to scar tissue. A biopsy that finds cancer is highly reliable, but a negative biopsy still misses residual cancer about 28% of the time.\u003c\/p\u003e\n\u003ch3\u003eCan surgery be skipped entirely after a complete response to neoadjuvant therapy?\u003c\/h3\u003e\n\u003cp\u003eNot for locally advanced breast cancer. No studies have specifically tested skipping surgery in these patients. A clinical trial exploring omission excluded locally advanced disease. Currently, no method accurately confirms complete response in a living patient without surgery, so surgery remains necessary.\u003c\/p\u003e\n\u003ch3\u003eIs breast-conserving surgery safe after neoadjuvant therapy for locally advanced breast cancer?\u003c\/h3\u003e\n\u003cp\u003eFor carefully selected patients who respond well, breast-conserving surgery appears safe. Studies show long-term recurrence rates similar to mastectomy when tumors shrink to 2 cm or less with at least 50% reduction. However, margin width is debated; some evidence suggests a 2 mm margin may be safer than 'no ink on tumor'.\u003c\/p\u003e\n\u003ch3\u003eIs immediate breast reconstruction safe after neoadjuvant therapy?\u003c\/h3\u003e\n\u003cp\u003eGenerally yes, but with cautions. Immediate reconstruction offers better satisfaction. However, patients with tumors larger than 3 cm had lower disease-free survival in one study, and T4 or inflammatory breast cancer had more complications and delayed radiation. Neoadjuvant therapy increases implant loss risk but not overall complications.\u003c\/p\u003e\n\u003ch3\u003eCan full lymph node removal be avoided if nodes became negative after treatment?\u003c\/h3\u003e\n\u003cp\u003eIn selected patients whose positive nodes convert to negative, sentinel lymph node biopsy may replace full dissection. Studies show low recurrence when at least three negative sentinel nodes are removed or targeted axillary dissection is used. However, for more advanced nodal disease (cN2-3), full dissection was linked to better survival in one large database study.\u003c\/p\u003e\n\u003ch3\u003eWhat is the reverse sequence approach for radiation and reconstruction?\u003c\/h3\u003e\n\u003cp\u003eIt means receiving radiation before surgery, after neoadjuvant therapy, followed by mastectomy and immediate reconstruction. Studies found this shortens overall treatment time by several weeks compared to the standard sequence, with similar survival and recurrence outcomes. It may help patients who need both reconstruction and radiation.\u003c\/p\u003e\n\u003c!-- ddn:faq:end --\u003e\n\n\u003ch2 id=\"source-information\"\u003eSource Information\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eOriginal Article Title:\u003c\/strong\u003e Surgery paradigm for locally advanced breast cancer following neoadjuvant systemic therapy\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOI:\u003c\/strong\u003e \u003ca href=\"https:\/\/doi.org\/10.3389\/fsurg.2024.1410127\" target=\"_blank\" rel=\"noopener\"\u003e10.3389\/fsurg.2024.1410127\u003c\/a\u003e\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eJournal:\u003c\/strong\u003e Frontiers in Surgery, Volume 11, Article 1410127\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePublication Date:\u003c\/strong\u003e September 6, 2024\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOI:\u003c\/strong\u003e 10.3389\/fsurg.2024.1410127\u003c\/p\u003e\n\n\u003cp\u003eThis patient-friendly article is based on peer-reviewed research. The original article is an open-access publication distributed under the terms of the Creative Commons Attribution License (CC BY), which permits unrestricted use, distribution, and reproduction with proper attribution. This summary was created to make the research accessible to patients and their families, but it does not replace individualized medical advice. Patients should discuss their specific situation with their oncology team, including surgeons, medical oncologists, and radiation oncologists, before making treatment decisions.\u003c\/p\u003e","brand":"DiagnosticDetectives.Com","offers":[{"title":"Default Title","offer_id":47423004147868,"sku":null,"price":0.0,"currency_code":"EUR","in_stock":true}],"url":"https:\/\/diagnosticdetectives.de\/products\/a-new-approach-to-breast-cancer-surgery-what-patients-should-know-about-treatment-after-neoadjuvant-therapy","provider":"DiagnosticDetectives.Com","version":"1.0","type":"link"}